In resectable ALK-rearranged NSCLC, ongoing an ALCHEMIST trial (NCT02194738) is evaluating adjuvant crizotinib at 250 mg twice daily versus observations in stage IB-IIIA NSCLC patients after standard care chemotherapy and/or radiotherapy. Here, ALK is linked to non-small cell lung carcinoma.